FindTrial
Sign In

Torvutatug samrotecan

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Endometrial CancerLung AdenocarcinomaLung Squamous Cell CarcinomaOvarian CancerPlatinum-sensitive Relapsed Epithelial Ovarian CancerPlatinum-sensitive Relapsed Fallopian Tube CancerPlatinum-sensitive Relapsed Primary Peritoneal Cancer

Phase 1

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RecruitingNCT05797168
AstraZenecaEndometrial Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma +1
Start: 2023-06-05End: 2028-08-04Target: 602Updated: 2026-08-21

Phase 3

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Not yet recruitingNCT07816666
AstraZenecaPlatinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
Start: 2026-09-29End: 2031-10-27Target: 600Updated: 2026-09-14

Related Papers

Abstract LB406: Synergistic antitumor effect of FRα TOP1i antibody drug conjugate, AZD5335, in combination with the PARP1 inhibitor, saruparib (AZD5305), in preclinical models of ovarian cancer
Cancer Research2024-04-05
Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
European Journal of Cancer Care2024-01-011 citations